迹还是泡沫?在资本市场中,药捷安康的市值表现可谓一枝独秀,短短三个月市值便突破千亿港元,这一成绩超越了信达生物、康方生物等一众明星生物科技股。然而,其基本面却与高市值形成鲜明反差,处于“无产品、无营收、无利润”的“三无”状态。2025年上半年,药捷安康收入为零,期内亏损1.23亿元。从研发管线来看,其核心产品替恩戈替尼虽有一定进展,但距离商业化仍需时日。目前该药针对胆管癌的注册性2期临床预计...
Source Link迹还是泡沫?在资本市场中,药捷安康的市值表现可谓一枝独秀,短短三个月市值便突破千亿港元,这一成绩超越了信达生物、康方生物等一众明星生物科技股。然而,其基本面却与高市值形成鲜明反差,处于“无产品、无营收、无利润”的“三无”状态。2025年上半年,药捷安康收入为零,期内亏损1.23亿元。从研发管线来看,其核心产品替恩戈替尼虽有一定进展,但距离商业化仍需时日。目前该药针对胆管癌的注册性2期临床预计...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.